{
  "docId": "019de074-2763-7087-8fbd-df19b6e58266",
  "docSlug": "1ca51573de190fbfcf19415b61000ddd",
  "documentTitle": "AstraZeneca | Investor Conference Presentation Deck | 18 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 18,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "thesis_headline",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide highlights the strategic fit of the CinCor acquisition (baxdrostat) into the existing CVRM pipeline.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2763-7087-8fbd-df19b6e58266/9",
  "deckHref": "/decks/019de074-2763-7087-8fbd-df19b6e58266",
  "deckJsonHref": "/decks/019de074-2763-7087-8fbd-df19b6e58266.json",
  "deckAnchorHref": "/decks/019de074-2763-7087-8fbd-df19b6e58266#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.58,
        "x": 0.03,
        "y": 0.22
      },
      "kind": "image",
      "text": "Pipeline mapping of CVRM diseases to drugs",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d7f9f874-d4ff-4a81-a9ce-3f1c80537d2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.77,
        "y": 0.45
      },
      "kind": "metric",
      "text": "7 million",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d979807-4637-4a6c-af38-0350475f2054",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.35,
        "x": 0.62,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "The clinical burden of treatment resistant hypertension. Hypertension, a silent killer: systolic blood pressure above 130 / 80 mm Hg. 7 million patients in the US are on three or more anti-hypertensive medicines and are still not at BP goal - treatment resistant.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "196f8846-7157-495a-8247-cc8c4cdf8a85",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.62,
        "y": 0.7
      },
      "kind": "paragraph",
      "text": "Current standard of care: ASIs and MRAs (spironolactone) target the aldosterone pathway to lower BP. MRAs -> undesirable androgenic side effects e.g., gynecomastia",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bfab6a12-8efe-4762-906a-302eeb3db299",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.03,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "BP = blood pressure; ASIs = aldosterone synthase inhibitors; MRAs = mineralocorticoid receptor antagonists. Collaboration partner: Ionis (eplontersen).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26f769dd-4553-4719-958e-fc7960dc1c29",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f5f24c3-ee42-4494-aa6e-32ad89449af2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "AstraZeneca positioned to lead in CVRM",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9770346b-ef3a-42d1-95a8-a8f61f138e10",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 9,
      "beatId": "d24e6f2d-ed7f-45f3-8426-4526ac01fda7",
      "arcName": "The Golden Circle",
      "arcSlug": "golden-circle",
      "beatName": "Thesis Headline",
      "beatSlug": null,
      "evidence": "A specific strategic action (acquisition) is highlighted to strengthen the pipeline.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    },
    {
      "to": 11,
      "from": 3,
      "beatId": "577d5e60-d812-43a3-83a5-243b94cfd455",
      "arcName": "The Golden Circle",
      "arcSlug": "golden-circle",
      "beatName": "Executive Summary",
      "beatSlug": null,
      "evidence": "Summarizing the company's position and strategy for growth.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "88983257-4d74-4000-ae54-8166a2051abc",
      "evidence": "The loop is visible in how the presentation starts with the company's mission and weaves through its growth strategy.",
      "position": 0,
      "objective": "To explain why AstraZeneca is positioned for growth and how it plans to achieve it",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.8,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    },
    {
      "to": 10,
      "from": 9,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "f577db34-3711-4966-ab1d-a155e7015552",
      "evidence": "The presentation highlights the strategic rationale for the acquisition at this time.",
      "position": 1,
      "objective": "To justify the timing of the acquisition of CinCor Pharma",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.7,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}